SCHEMBL1665644

SCHEMBL1665644

c1ccc(-c2cc3ncccn3n2)cc1

nearest known ligand 0.54

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
APOBEC3A P31941 1/20 0.54
APOBEC3G Q9HC16 1/20 0.54
NPC1 O15118 6/20 0.53
RAB9A P51151 5/20 0.53
MAPT P10636 3/20 0.53
L3MBTL1 Q9Y468 2/20 0.53
LMNA P02545 1/20 0.53
DYRK1A Q13627 2/20 0.47
KDM4E B2RXH2 3/20 0.46
ALDH1A1 P00352 2/20 0.46
HPGD P15428 2/20 0.46
GLA P06280 1/20 0.46
HSD17B10 Q99714 1/20 0.46
MAP4K4 O95819 3/20 0.43
PRKACA P17612 3/20 0.43
CDK8 P49336 3/20 0.43
CSF1R P07333 2/20 0.43
KDR P35968 2/20 0.43
MAP2K1 Q02750 2/20 0.43
ACVR1 Q04771 2/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1015835 0.89 DYRK1A (0.62) APOBEC3AAPOBEC3GNPC1RAB9AMAPT
SCHEMBL30708692 0.88 APOBEC3A (0.61) APOBEC3AAPOBEC3GNPC1RAB9AMAPT
Hydrochloric Acid SCHEMBL25276515 0.87 DYRK1A (0.60) APOBEC3AAPOBEC3GNPC1RAB9AMAPT
SCHEMBL2971288 0.87 CYP2A6 (0.50) APOBEC3AAPOBEC3GNPC1RAB9AMAPT
SCHEMBL5052722 0.86 RAB9A (0.49) APOBEC3AAPOBEC3GNPC1RAB9AMAPT
SCHEMBL5060955 0.86 APOBEC3A (0.49) APOBEC3AAPOBEC3GNPC1RAB9AMAPT
SCHEMBL4154898 0.86 MAPT (0.49) APOBEC3AAPOBEC3GNPC1RAB9AMAPT
SCHEMBL30375110 0.85 GRM5 (0.47) APOBEC3AAPOBEC3GNPC1RAB9AMAPT
SCHEMBL30033563 0.85 BACE1 (0.47) APOBEC3AAPOBEC3GNPC1RAB9AMAPT
SCHEMBL30798766 0.85 APOBEC3A (0.51) APOBEC3AAPOBEC3GNPC1RAB9AMAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 44 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-111388477-B Application of 2-phenylpyrazole [1,5-a ] pyrimidine compound as tumor drug resistance reversal agent 山东师范大学 2021-06-25 CN claimed
US-12384787-B2 Fused heterocyclic compounds and their use as pest control agents PI INDUSTRIES LTD (IN) 2025-08-12 US disclosed
US-20220251094-A1 FUSED HETEROCYCLIC COMPOUNDS AND THEIR USE AS PEST CONTROL AGENTS PI INDUSTRIES LTD. (IN) 2022-08-11 US disclosed
CN-111388477-B Application of 2-phenylpyrazole [1,5-a ] pyrimidine compound as tumor drug resistance reversal agent 山东师范大学 2021-06-25 CN disclosed
CN-111388477-B Application of 2-phenylpyrazole [1,5-a ] pyrimidine compound as tumor drug resistance reversal agent 山东师范大学 2021-06-25 CN disclosed
CN-111388477-A Application of 2-phenylpyrazole [1,5-a ] pyrimidine compound as tumor drug resistance reversal agent 山东师范大学 2020-07-10 CN disclosed
CN-111388477-A Application of 2-phenylpyrazole [1,5-a ] pyrimidine compound as tumor drug resistance reversal agent 山东师范大学 2020-07-10 CN disclosed
EP-3507290-A1 INHIBITORS OF CELLULAR METABOLIC PROCESSES Agios Pharmaceuticals, Inc. (US) 2019-07-10 EP disclosed
WO-2018045071-A1 INHIBITORS OF CELLULAR METABOLIC PROCESSES AGIOS PHARMACEUTICALS, INC. (US) 2018-03-08 WO disclosed
US-8586623-B2 2-oxo-1-pyrrolidine derivatives, processes for preparing them and their uses UCB PHARMA, S.A. (BE) 2013-11-19 US disclosed
US-20090312333-A1 2-Oxo-1-Pyrrolidine Derivatives, Processes for Preparing Them and Their Uses UCB PHARMA, S.A. (BE) 2009-12-17 US disclosed
US-20090156607-A1 2-OXO-1-PYRROLIDINE DERIVATIVES UCB, S.A. (BE) 2009-06-18 US disclosed
US-20090156607-A1 2-OXO-1-PYRROLIDINE DERIVATIVES UCB, S.A. (BE) 2009-06-18 US disclosed
US-20090156607-A1 2-OXO-1-PYRROLIDINE DERIVATIVES UCB, S.A. (BE) 2009-06-18 US disclosed
EP-1912966-A2 2-OXO-1-PYRROLIDINE DERIVATIVES AND THEIR THERAPEUTIC USE ON THE CENTRAL NERVOUS SYSTEM UCB, S.A. (BE) 2008-04-23 EP disclosed
EP-1891042-A2 2-OXO-1-PYRROLIDINE DERIVATIVES, PROCESSES FOR PREPARING THEM AND THEIR THERAPEUTIC USE ON THE CENTRAL NERVOUS SYSTEM UCB Pharma, S.A. (BE) 2008-02-27 EP disclosed
CN-1951939-A Novel pyrrole derivatives as pharmaceutical agents LILLY CO ELI (US) 2007-04-25 CN disclosed
WO-2006128693-A2 2 -OXO-I -PYRROLIDINE DERIVATIVES/ PROCESSES FOR PREPARING THEM AND THEIR THERAPEUTIC USE ON THE CENTRAL NERVOUS SYSTEM UCB PHARMA, S.A. (BE) 2006-12-07 WO disclosed
WO-2006128692-A2 2-OXO-1-PYRROLIDINE DERIVATIVES AND THEIR THERAPEUTIC USE ON THE CENTRAL NERVOUS SYSTEM UCB PHARMA, S.A. (BE) 2006-12-07 WO disclosed
CN-1269820-C Novel pyrrole derivatives as medicaments LILLY CO ELI (US) 2006-08-16 CN disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-12384787-B2 Fused heterocyclic compounds and their use as pest control agents DDT, ACHE, KEAP1 APOBEC3A 3588/4885APOBEC3G 3012/4885NPC1 3338/4885
US-20090312333-A1 2-Oxo-1-Pyrrolidine Derivatives, Processes for Preparing Them and Their Uses CYP3A4, CYP1B1, CYP2D6 APOBEC3A 709/4885APOBEC3G 472/4885NPC1 416/4885
US-20090156607-A1 2-OXO-1-PYRROLIDINE DERIVATIVES OPRD1, PPOX, CYP2D6 APOBEC3A 1173/4885APOBEC3G 910/4885NPC1 404/4885
US-20220251094-A1 FUSED HETEROCYCLIC COMPOUNDS AND THEIR USE AS PEST CONTROL AGENTS DDT, ACHE, KEAP1 APOBEC3A 3588/4885APOBEC3G 3012/4885NPC1 3338/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.